AI Science Tracker
EN

CHA University

1 discovery from 2021

Discoveries

Deep learning guides discovery of the STB-C017 kynurenine-pathway inhibitor

Source check: Source checked. Not independent scientific confirmation.

Finding: Convolutional neural-network models trained on prior IDO and TDO bioactivity guided screening and assay-driven refinement, leading to STB-C017. The study reports dual inhibition in biochemical and cell assays, reduced kynurenine in mice and enhanced antitumor responses when combined with immune-checkpoint inhibitors in mouse models. This entry represents the November 2021 journal version; an earlier 2021 Research Square manuscript concerns the same study, and efficacy or safety in patients is not established.

Technology: Convolutional neural-network bioactivity classifiers

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Separate CNN classifiers ranked potential IDO and TDO inhibitors. Four cycles of predictions, selection and measured assays updated the models before lead selection.
Test and result
Biochemical and cell assays tested IDO/TDO inhibition, followed by mouse studies of kynurenine suppression and antitumor combinations in the originating study.
Limitation / still unknown
Clinical efficacy and safety are not established; originating-study assays and mouse experiments are not independent replication.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://doi.org/10.1080/2162402X.2021.2005280 · https://pmc.ncbi.nlm.nih.gov/articles/PMC8632076/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Primary full article Methods, result-specific experiments, discussion, affiliations and journal publication metadata; no independent replication performed..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.